| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/20/2003 | WO2003013614A1 Collagen-containing oral preparations, drugs and quasi drugs |
| 02/20/2003 | WO2003013609A1 Sustained-release medicines |
| 02/20/2003 | WO2003013603A1 Modulators of p-selectin glycoprotein ligand 1 |
| 02/20/2003 | WO2003013602A1 Inhibitors of her3 activity |
| 02/20/2003 | WO2003013593A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 02/20/2003 | WO2003013591A2 Pharmaceutical composition containing caspase-8 and/or caspase-9 useful for overcoming glucocorticoid- and cancer therapy-induced apoptosis resistance of tumours |
| 02/20/2003 | WO2003013590A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer |
| 02/20/2003 | WO2003013574A1 Melanin-concentrating hormone antagonists |
| 02/20/2003 | WO2003013559A1 Bile acid absorbent/adsorbent |
| 02/20/2003 | WO2003013555A1 Method for amplifying expression from a cell specific promoter |
| 02/20/2003 | WO2003013554A2 Aromatase inhibitors from broussonetia papyrifera |
| 02/20/2003 | WO2003013545A1 Novel benzo-fused heterocycles as endothelin antagonisits |
| 02/20/2003 | WO2003013541A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives |
| 02/20/2003 | WO2003013540A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | WO2003013539A1 Neuroprotective drug |
| 02/20/2003 | WO2003013537A2 Irinotecan for treatment of cancer |
| 02/20/2003 | WO2003013536A2 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | WO2003013535A2 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | WO2003013534A2 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | WO2003013533A2 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | WO2003013531A1 Phenyl derivatives as factor xa inhibitors |
| 02/20/2003 | WO2003013528A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists. |
| 02/20/2003 | WO2003013523A1 Sh3 protein domains and their ligands |
| 02/20/2003 | WO2003013517A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | WO2003013513A1 Stable emulsion composition |
| 02/20/2003 | WO2003013509A1 N-phenylpyrrole guanidine derivatives as melanocortin reception ligands |
| 02/20/2003 | WO2003013503A1 C-2' methylated derivatives of paclitaxel for use as antitumour agents |
| 02/20/2003 | WO2003013502A1 Compounds which mimic the chemical and biological properties of discodermolide |
| 02/20/2003 | WO2003013488A2 Methods and compositions for inhibiting rad51 |
| 02/20/2003 | WO2003013485A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 02/20/2003 | WO2003013484A2 N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents |
| 02/20/2003 | WO2003013475A1 Injectable foam and novel pharmaceutical applications thereof |
| 02/20/2003 | WO2003013434A2 Methods and compositions for treating diseases associated with excesses in ace |
| 02/20/2003 | WO2003013431A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/20/2003 | WO2003013430A2 Benzoquinone ansamycins |
| 02/20/2003 | WO2003013426A2 Multivalent synthetic vaccine for cancer |
| 02/20/2003 | WO2003013422A2 Methods for the treatment and prognosis of leukemia and other cancer types |
| 02/20/2003 | WO2002100858A3 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
| 02/20/2003 | WO2002099138A3 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2002098369A3 Mutant forms of cholera holotoxin as an adjuvant |
| 02/20/2003 | WO2002098360A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002094980A3 Phytocystatin |
| 02/20/2003 | WO2002089919A3 Usage of zinc for preventing tnf-induced pathology during cancer therapy |
| 02/20/2003 | WO2002086085A3 Human timp-1 antibodies |
| 02/20/2003 | WO2002083733A3 Polynucleotides and polypeptides of the ifnalpha-6 gene |
| 02/20/2003 | WO2002080889A3 A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer |
| 02/20/2003 | WO2002079183A8 Halogenated rhodamine derivatives and applications thereof |
| 02/20/2003 | WO2002074742A3 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 02/20/2003 | WO2002074246A3 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 02/20/2003 | WO2002072585A3 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/20/2003 | WO2002072003A3 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 02/20/2003 | WO2002070525A3 Nitrogen-based camptothecin derivatives |
| 02/20/2003 | WO2002068548A9 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 02/20/2003 | WO2002067998A3 Devices and methods for the treatment of cancer |
| 02/20/2003 | WO2002064126A3 Method of treating of demyelinating diseases or conditions |
| 02/20/2003 | WO2002054933A3 Method for photodynamic therapy and applicator for carrying out said therapy |
| 02/20/2003 | WO2002053170A3 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 02/20/2003 | WO2002050058A8 Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production |
| 02/20/2003 | WO2002045738A3 Vaccine composition containing transforming growth factor alpha |
| 02/20/2003 | WO2002042295A3 Peptides as met-ap2 inhibitors |
| 02/20/2003 | WO2002039999A3 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition |
| 02/20/2003 | WO2002030882A9 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002029088A9 Highly expressible genes |
| 02/20/2003 | WO2002028420A9 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules |
| 02/20/2003 | WO2002026950A3 Transferases |
| 02/20/2003 | WO2002026193A9 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 02/20/2003 | WO2002014368A8 Proteins and nucleic acids encoding the same |
| 02/20/2003 | WO2001079187A8 Substituted 1,4-thiazepine and analogs and their use as activators of caspases |
| 02/20/2003 | WO2001056547B1 Preparation of aqueous clear solution dosage forms with bile acids |
| 02/20/2003 | US20030036645 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 02/20/2003 | US20030036642 Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| 02/20/2003 | US20030036628 p21 peptides |
| 02/20/2003 | US20030036568 Permeation enhancers |
| 02/20/2003 | US20030036552 Novel compounds |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036539 Use of 2-ME in promotion of apoptosis in the prevention of initial onset and recurrence of existing cancers |
| 02/20/2003 | US20030036538 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest. |
| 02/20/2003 | US20030036536 Substituted benzylthioacetic acids and esters |
| 02/20/2003 | US20030036524 Transfecting with a polynucleotide that comprises a prodrug metabolising gene, and a promoter capable of selectively promoting the transcription of the prodrug metabolising gene in said endothelial cell; and delivering said prodrug |
| 02/20/2003 | US20030036521 Also using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues. |
| 02/20/2003 | US20030036513 Reducing the effective dose of an anti-cancer agent by administering a redox clamping agent, especially Mesna, in conjunction with an anti-cancer agent. |
| 02/20/2003 | US20030036501 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 02/20/2003 | US20030036199 Kit for use in the diagnosis and treatment of cancer |
| 02/20/2003 | US20030036185 Novel amino acid sequences for human kidney cadherin-like polypeptides |
| 02/20/2003 | US20030036184 Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| 02/20/2003 | US20030036175 Depletion or removal of endotoxins from solution; obtain solution, incubate with chromatographic column, elute, recover endotoxin free solution |
| 02/20/2003 | US20030036112 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders |
| 02/20/2003 | US20030036078 P5CRs as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | US20030036076 CADs as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | US20030036075 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders |
| 02/20/2003 | US20030035847 Acid mixture; anticancer, antitumor agents |
| 02/20/2003 | US20030035829 Liposomal compositions for the delivery of nucleic acid catalysts |
| 02/20/2003 | US20030035804 In situ drug delivery |
| 02/20/2003 | US20030035800 Glycosylated humanized B-cell specific antibodies |
| 02/20/2003 | US20030035799 Glycosylated antibody |
| 02/20/2003 | US20030035789 Purging lymphocytes |
| 02/20/2003 | US20030035788 Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
| 02/20/2003 | US20030035787 Polyanhydrides with biologically active degradation products |